SCHEMBL5138064

SCHEMBL5138064

CCCCN(Cc1ccccc1)Cc1c(-c2ccc(F)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
CRHR1 P34998 2/20 0.42
TSHR P16473 6/20 0.41
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40
ATP4A P20648 2/20 0.39
ATP4B P51164 2/20 0.39
KDM4E B2RXH2 5/20 0.38
ALDH1A1 P00352 5/20 0.38
CYP3A4 P08684 5/20 0.38
HPGD P15428 5/20 0.38
HSD17B10 Q99714 5/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136574 0.97 C5AR1 (0.46) C5AR1CRHR1TSHRATP4AATP4B
SCHEMBL5135469 0.94 C5AR1 (0.43) C5AR1CRHR1TSHRATP4AATP4B
SCHEMBL649161 0.94 C5AR1 (0.47) C5AR1CRHR1TSHRATP4AATP4B
SCHEMBL5135240 0.93 C5AR1 (0.42) C5AR1CRHR1TSHRMAPK13MAPK12
SCHEMBL5136220 0.93 C5AR1 (0.46) C5AR1CRHR1TSHRMAPK13MAPK12
SCHEMBL5136813 0.93 C5AR1 (0.41) C5AR1CRHR1TSHRMAPK13MAPK12
SCHEMBL5072370 0.93 C5AR1 (0.47) C5AR1TSHRKDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL648480 0.93 C5AR1 (0.46) C5AR1CRHR1TSHRATP4AATP4B
SCHEMBL5137489 0.92 C5AR1 (0.48) C5AR1CRHR1TSHRATP4AATP4B
SCHEMBL5136250 0.91 DRD2 (0.43) C5AR1CRHR1TSHRATP4AATP4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed